title: [The combination of indacaterol and glycopyrronium has effects on symptoms, lung function, and rate of exacerbations in COPD patients].
abstract: Long-acting bronchodilators are the mainstay of pharmacological therapy for chronic obstructive pulmonary disease (COPD). This paper reviews the efficacy of the once-daily fixed-dose dual bronchodilator combination of indacaterol and glycopyrronium in COPD patients. Compared with single therapy with indacaterol, glycopyrronium and tiotropium and fixed combination salmeterol/fluticasone, fixed-dose indacaterol/glycopyrronium has clinically relevant effects on symptoms, health status, lung function, and rate of exacerbations and by that suggests a potential for dual bronchodilation as an important maintenance therapeutic option for some patients with COPD.
authors.affiliation: Lungemedicinsk Afdeling, Hvidovre -Hospital, Kettegård Allé 30, 2650 Hvidovre. E-mail: csulrik@dadlnet.dk.
authors.forename: Charlotte Suppli
authors.initials: CS
authors.lastname: Ulrik
mesh_terms: D000280:Administration, Inhalation; D058666:Adrenergic beta-2 Receptor Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D018450:Disease Progression; D004338:Drug Combinations; D005541:Forced Expiratory Volume / Q000187:drug effects; D006024:Glycopyrrolate / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007189:Indans / Q000008:administration & dosage / Q000627:therapeutic use*; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D011788:Quality of Life; D015363:Quinolones / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D004338:Drug Combinations; D007189:Indans; D018727:Muscarinic Antagonists; D015363:Quinolones; C510790:indacaterol; D006024:Glycopyrrolate